What can you take for joint soreness?

Would a cream for swelling suit you better than a pill?

An anti-inflammatory cream is medicine that lowers swelling and soreness near a hand or knee. Less medicine enters the blood than with a pill. That may reduce stomach, kidney, heart, and blood-pressure harm, but those risks don't disappear.

Anti-inflammatory pills, such as ibuprofen or naproxen, may help more than one sore area. They can cause stomach bleeding, kidney strain, or higher blood pressure. If you have an ulcer, weak kidneys, heart trouble, or take a blood thinner, talk with your doctor or pharmacist about the least harmful choice before using a cream or pill.

Don't use two swelling-reducing medicines together unless your doctor or pharmacist has reviewed the pair. Notice whether the medicine helps you sleep, walk, or rise from a chair. If it doesn't make a useful task easier, ask whether continued use is worth the risk.

What are acetaminophen, duloxetine, and stronger pain pills for?

Acetaminophen is a common pain reliever, but it doesn't reduce swelling. On average, it gives little help for arthritis soreness. It also hides inside many cold, sleep, and prescription products, so read every active-ingredient label to avoid taking it twice.

Doctors sometimes use duloxetine for long-lasting soreness because it can reduce pain messages carried through the nerves. It was first used for depression, but that doesn't mean your joint ache is imagined. Its average help is modest, and nausea, dizziness, sleep changes, and other medicines still matter.

Opioids are strong prescription pain pills, and their average help for long-lasting joint soreness is small. They can cause sleepiness, constipation, falls, and dependence. If you're already taking one, don't stop suddenly; ask the prescriber to review the dose, benefit, and safest next step.

Sources

1. OARSI's 2019 guideline is the only major osteoarthritis guideline that grades treatments separately for people with disease in MULTIPLE joints. Its Core Treatments for polyarticular OA are arthritis education and structured land-based exercise. Critically, intra-articular corticosteroid and intra-articular hyaluronic acid were Level 1B/2 options for knee OA only and were NOT recommended for hip or polyarticular OA; oral NSAIDs were not recommended at all for people with cardiovascular comorbidity or frailty; and paracetamol/acetaminophen was conditionally not recommended.

   Bannuru RR, Osani MC, Vaysbrot EE, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.. Osteoarthritis and Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

2. A network meta-analysis of 192 randomised trials in 102,829 patients with knee or hip osteoarthritis found that five oral preparations - diclofenac 150 mg/day, etoricoxib 60 and 90 mg/day, and rofecoxib 25 and 50 mg/day - had a 99% or greater probability of exceeding the minimal clinically important reduction in pain. Topical diclofenac (70-81 and 140-160 mg/day) had a 92.3% or greater probability. Every opioid studied had a 53% or LOWER probability of exceeding that threshold.

   da Costa BR, Pereira TV, Saadat P, et al. — Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis.. BMJ, 2021. DOI: 10.1136/bmj.n2321.

3. A meta-analysis of 96 randomised trials including 26,169 participants with chronic non-cancer pain found that compared with placebo, opioids reduced pain by a weighted mean of 0.69 cm on a 10 cm visual analogue scale - well under the 1 cm minimally important difference - with a modelled 11.9% (95% CI 9.7-14.1) risk difference for achieving that minimal difference, and improved physical function by 2.04 points on a 100-point scale where the minimally important difference is 5 points.

   Busse JW, Wang L, Kamaleldin M, et al. — Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis.. JAMA, 2018. DOI: 10.1001/jama.2018.18472.

4. CDC's 2022 clinical practice guideline for prescribing opioids covers acute (under 1 month), subacute (1-3 months) and chronic (over 3 months) pain in outpatients aged 18 and over, built on GRADE. It addresses whether to initiate opioids at all, opioid selection and dosage, duration and follow-up, and assessing risk and harms - and states that people with pain should receive appropriate pain treatment with careful consideration of the benefits and risks of ALL treatment options in the context of the patient's circumstances.

   Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R — CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.. MMWR Recommendations and Reports, 2022. DOI: 10.15585/mmwr.rr7103a1.

5. A Cochrane network meta-analysis of 176 studies and 28,664 participants examined 25 different antidepressants for chronic pain. Duloxetine was consistently the highest-ranked drug with moderate-to-high certainty evidence: at the standard 60 mg dose it gave an odds ratio of 1.91 (95% CI 1.69-2.17) for substantial pain relief and a standardised mean difference of -0.31 (95% CI -0.39 to -0.24) for pain intensity, with the standard dose as effective as the high dose. Evidence for every other antidepressant was low certainty, safety evidence was very low certainty throughout, and there is no reliable evidence for long-term efficacy of any of them.

   Birkinshaw H, Friedrich CM, Cole P, et al. — Antidepressants for pain management in adults with chronic pain: a network meta-analysis.. Cochrane Database of Systematic Reviews, 2023. DOI: 10.1002/14651858.CD014682.pub2.

6. A meta-analysis of 13 randomised trials in 4,201 participants across four countries found duloxetine statistically superior to placebo for 24-hour average pain, quality of life, physical function and global impression in chronic musculoskeletal pain, with no difference in serious adverse events.

   Ma X, Zhou S, Sun L, et al. — Efficacy and safety of duloxetine in chronic musculoskeletal pain: a systematic review and meta-analysis.. BMC Musculoskeletal Disorders, 2023. DOI: 10.1186/s12891-023-06488-6.